Attenuation of Hypertension Development by Aminoguanidine in Spontaneously Hypertensive Rats: Role of Methylglyoxal

American Journal of Hypertension

Volumn 20, Issue 6, 2007, Pages 629-636

  Wang, Xiaoxia ^a   Chang, Tuanjie ^a   Jiang, Bo ^a   Desai, Kaushik ^a   Wu, Lingyun ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

advanced glycation end products; hypertension; Methylglyoxal

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ACETYLCHOLINE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ARGPYRAMIDINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FREE RADICAL; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYLGLYOXAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MESENTERIC ARTERY; MORPHOLOGY; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TISSUE INJURY; VASCULAR TISSUE; VASODILATATION; WISTAR KYOTO RAT;

ANIMALS; AORTA; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FREE RADICALS; GLUTATHIONE; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HYPERTENSION; MALE; MESENTERIC ARTERIES; NITRIC OXIDE SYNTHASE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PYRUVALDEHYDE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 34248645698     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.12.003     Document Type: Article

References (31)

1. Singh R., Barden A., Mori T., and Beilin L. Advanced glycation end-products: a review. Diabetologia 44 (2001) 129-146
2. Brownlee M., Cerami A., and Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318 (1988) 1315-1321
3. Shinohara M., Thornalley P.J., Giardino I., Beisswenger P., Thorpe S.R., Onorato J., and Brownlee M. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101 (1998) 1142-1147
4. Kalapos M.P. Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicol Lett 110 (1999) 145-175
5. Shipanova I.N., Glomb M.A., and Nagaraj R.H. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch Biochem Biophys 344 (1997) 29-36
6. Wu L. Is methylglyoxal a causative factor for hypertension development?. Can J Physiol Pharmacol 84 (2006) 129-139
7. Mizutani K., Ikeda K., Kawai Y., and Yamori Y. Biomechanical properties and chemical composition of the aorta in genetic hypertensive rats. J Hypertens 17 (1999) 481-487
8. Wang X., Desai K., Juurlink B.H., de Champlain J., and Wu L. Gender-related differences in advanced glycation endproducts, oxidative stress markers and nitric oxide synthases in rats. Kidney Int 69 (2006) 281-287
9. Wu L., and Juurlink B.H. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39 (2002) 809-814
10. Wang X., Desai K., Chang T., and Wu L. Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 23 (2005) 1565-1573
11. Wang X., Desai K., Clausen J.T., and Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 66 (2004) 2315-2321
12. Chaplen F.W., Fahl W.E., and Cameron D.C. Method of determination of free intracellular and extracellular meththylglyoxal in animal cells grown in culture. Anal Biochem 238 (1996) 171-178
13. Wu L., Noyan Ashraf M.H., Facci M., Wang R., Paterson P.G., Ferrie A., and Juurlink B.H. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci USA 101 (2004) 7094-7099
14. Wu R., Lamontagne D., and de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 105 (2002) 387-392
15. Chang T., Wang R., and Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med 38 (2005) 286-293
16. deBlois D., Tea B.S., Than V.D., Tremblay J., and Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 29 (1997) 340-349
17. Chan V., Hoey A., and Brown L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol 148 (2006) 902-908
18. Brownlee M., Vlassara H., Kooney A., Ulrich P., and Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232 (1986) 1629-1632
19. Hammes H.P., Martin S., Federlin K., Geisen K., and Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88 (1991) 11555-11558
20. Corman B., Duriez M., Poitevin P., Heudes D., Bruneval P., Tedgui A., and Levy B.I. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 95 (1998) 1301-1306
21. Thornalley P.J., Yurek-George A., and Argirov O.K. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60 (2000) 55-65
22. Yu P.H., and Zuo D.M. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetología 40 (1997) 1243-1250
23. Ekblom J. Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus. Pharmacol Res 37 (1998) 87-92
24. Fu M.X., Wells-Knecht K.J., Blackledge J.A., Lyons T.J., Thorpe S.R., and Baynes J.W. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43 (1994) 676-683
25. de Champlain J., Wu R., Girouard H., Karas M., El Midaoui A., Laplante M.A., and Wu L. Oxidative stress in hypertension. Clin Exp Hypertens 26 (2004) 593-601
26. Giardino I., Fard A.K., Hatchell D.L., and Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47 (1998) 1114-1120
27. G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 199 (1994) 147-154
28. Wei C.L., Hon W.M., Lee K.H., and Khoo H.E. Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct-ligated rats. Liv Intl 25 (2005) 647-656
29. Rojas A., Romay S., Gonzalez D., Herrera B., Delgado R., and Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 86 (2000) E50-E54
30. Mulvany M.J. Small artery remodeling in hypertension. Curr Hypertens Rep 4 (2002) 49-55
31. Berry C.L., Greenwald S.E., and Menahem N. Effect of beta-aminopropionitrile on the static elastic properties and blood pressure of spontaneously hypertensive rats. Cardiovasc Res 15 (1981) 373-381